INMB vs. ABOS, ZURA, KOD, OPT, IPHA, ADVM, CGEN, ELEV, IPSC, and XFOR
Should you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Kodiak Sciences (KOD), Opthea (OPT), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), Compugen (CGEN), Elevation Oncology (ELEV), Century Therapeutics (IPSC), and X4 Pharmaceuticals (XFOR). These companies are all part of the "biological products, except diagnostic" industry.
INmune Bio (NASDAQ:INMB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
INmune Bio received 119 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 75.69% of users gave INmune Bio an outperform vote while only 64.29% of users gave Acumen Pharmaceuticals an outperform vote.
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 36.1% of INmune Bio shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
INmune Bio presently has a consensus target price of $16.00, indicating a potential upside of 61.29%. Acumen Pharmaceuticals has a consensus target price of $12.25, indicating a potential upside of 264.58%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than INmune Bio.
Acumen Pharmaceuticals has a net margin of 0.00% compared to INmune Bio's net margin of -26,333.59%. Acumen Pharmaceuticals' return on equity of -23.40% beat INmune Bio's return on equity.
INmune Bio has higher revenue and earnings than Acumen Pharmaceuticals. INmune Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, INmune Bio and INmune Bio both had 10 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 0.67 beat INmune Bio's score of -0.03 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
INmune Bio has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
Summary
Acumen Pharmaceuticals beats INmune Bio on 9 of the 15 factors compared between the two stocks.
Get INmune Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INmune Bio Competitors List
Related Companies and Tools
